{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T23:11:08Z","timestamp":1723677068899},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.ejim.2010.09.016","type":"journal-article","created":{"date-parts":[[2010,10,28]],"date-time":"2010-10-28T08:17:04Z","timestamp":1288253824000},"page":"473-477","source":"Crossref","is-referenced-by-count":1,"title":["Treating high blood pressure: Is reaching the target more important than the means? Yes, the target is more important"],"prefix":"10.1016","volume":"21","author":[{"given":"Ettore","family":"Bartoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Piero","family":"Carnevale Schianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo","family":"Sainaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2010.09.016_bb0005","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)90944-Z","article-title":"Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context","volume":"335","author":"Collins","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(90)90878-9","article-title":"Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias","volume":"335","author":"MacMahon","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0015","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/01.hjh.0000170370.41387.1b","article-title":"Evidence-based medicine in hypertension: what type of evidence?","volume":"23","author":"Zanchetti","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2010.09.016_bb0020","first-page":"481","article-title":"Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study","volume":"12","author":"Th\u00fcrmer","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2010.09.016_bb0025","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and for the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2010.09.016_bb0030","first-page":"CD004349","article-title":"Treatment blood pressure targets for hypertension","volume":"3","author":"Arguedas","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2010.09.016_bb0035","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.09.016_bb0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/HJH.0b013e3283298ea2","article-title":"Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension","volume":"27","author":"Zanchetti","year":"2009","journal-title":"J Hypertens"},{"issue":"Suppl I","key":"10.1016\/j.ejim.2010.09.016_bb0045","first-page":"I106","article-title":"The Hypertension Detection and Follow-up Program. A progress report","volume":"40","year":"1977","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2010.09.016_bb0050","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.273.18.1450","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2010.09.016_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00004872-199204000-00009","article-title":"Sympathomoderating influence of benazepril in essential hypertension","volume":"10","author":"Giannattasio","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2010.09.016_bb0060","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0065","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1172\/JCI118807","article-title":"Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure","volume":"98","author":"Levy","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2010.09.016_bb0070","first-page":"S24","article-title":"Evidence-based medicine and ACE inhibition","volume":"32","author":"Borghi","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2010.09.016_bb0075","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmj.303.6799.385","article-title":"Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham study","volume":"303","author":"D'Agostino","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2010.09.016_bb0080","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jama.267.9.1213","article-title":"The effects of nonpharmacologic intervention on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I","volume":"267","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2010.09.016_bb0085","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0090","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2010.09.016_bb0095","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","author":"Turnbull","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2010.09.016_bb0100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","article-title":"Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003","volume":"21","author":"Staessen","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2010.09.016_bb0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00004872-199409000-00001","article-title":"Molecular aspects of signal transduction of shear stress in the endothelial cell","volume":"12","author":"Malek","year":"1994","journal-title":"J Hypertens"},{"issue":"Suppl 9","key":"10.1016\/j.ejim.2010.09.016_bb0110","first-page":"39","article-title":"Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis","volume":"10","author":"Weidmann","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2010.09.016_bb0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00005344-199603000-00016","article-title":"Indapamide is as effective as captopril in the control of microalbuminuria in diabetes","volume":"27","author":"Molyneaux","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2010.09.016_bb0120","first-page":"1363","article-title":"Long term impact of lisinopril and atenolol on kidney function in NIDdiabetes mellitus patients with diabetic nephropathy (Abstract)","volume":"7","author":"Nielsen","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2010.09.016_bb0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7326\/0003-4819-125-3-199608010-00007","article-title":"Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists","volume":"125","author":"Bakris","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2010.09.016_bb0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ki.1972.83","article-title":"Sieving equations and effective glomerular filtration pressure","volume":"2","author":"Lambert","year":"1972","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2010.09.016_bb0140","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-bind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0145","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1001\/jama.288.23.3039","article-title":"The verdict from ALLHAT-thiazide diuretics are the preferred initial therapy for hypertension","volume":"288","author":"Appel","year":"2002","journal-title":"JAMA"},{"issue":"Suppl 5A","key":"10.1016\/j.ejim.2010.09.016_bb0150","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/S0002-9343(01)00665-9","article-title":"Current utilization trends for beta-blockers in cardiovascular disease","volume":"110","author":"Kennedy","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2010.09.016_bb0155","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of Ace inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.09.016_bb0165","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0170","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ejim.2010.09.016_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjhyper.2005.10.009","article-title":"Role of outcome trials in providing information on antihypertensive treatment: importance and limitations","volume":"19","author":"Mancia","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2010.09.016_bb0180","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.110.960120","article-title":"Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"122","author":"Mancia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2010.09.016_bb0185","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for End-point reduction in hypertension study (LIFE): a randomized trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.09.016_bb0190","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2010.09.016_bb0195","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1523-1755.2002.00261.x","article-title":"ACE inhibitors and AT-1 receptor antagonists: is two better than one?","volume":"61","author":"Noris","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2010.09.016_bb0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004872-200201000-00018","article-title":"Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade","volume":"20","author":"Ferrari","year":"2002","journal-title":"J Hypertens"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510001998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510001998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T06:22:20Z","timestamp":1544163740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620510001998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0953620510001998"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2010.09.016","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}